


Healthcare News Roundup: Drug Delivery
HSMN NewsFeed - 26 Jul 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
HSMN NewsFeed - 16 Jul 2018
enGene Appoints Veteran Life Sciences Executive Jason D. Hanson as Chief Executive Officer and President
enGene Appoints Veteran Life Sciences Executive Jason D. Hanson as Chief Executive Officer and President
HSMN NewsFeed - 11 Jul 2018
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
